This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Abiomed Appoints Susan Vissers Lisa As Senior Director Of Investor Relations And Corporate Development

Abiomed Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced the appointment of Susan Vissers Lisa, CFA, as Senior Director of Investor Relations and Corporate Development. Ms. Lisa brings more than 20 years of capital markets and healthcare experience, as well as an extensive background in medical technology, financial analysis, and sales and marketing management.

“We are extremely pleased to have Susie Lisa on board during an exciting time of continued growth and opportunity for the Company,” said Michael R. Minogue, Chairman, President and Chief Executive Officer of Abiomed. “With a unique background across financial markets, the medical technology sector, and healthcare investors, Susie is well positioned to help Abiomed continue to grow shareholder value as we execute our plan to recover hearts with cost-effective patient outcomes.”

Prior to joining Abiomed, Ms. Lisa was a Managing Director at Bank of America Merrill Lynch. During her 12 year tenure, she was head of Americas Specialist Sales from 2009 to 2011, managing a team of 20+ dedicated sector sales specialists across all sectors of the S&P, while also providing dedicated healthcare sales coverage to major institutional investor clients. In her equity research sales role from 2001 to 2011, Ms. Lisa helped market Bank of America Merrill Lynch’s healthcare equity research and capital markets transactions to some of the most sophisticated healthcare investors in the U.S. and Europe, also working closely with colleagues in trading, derivatives, capital markets, and investment banking to help best position healthcare corporations with investors and drive strong investment returns.

Prior to her sales role, Ms. Lisa spent four years as a medical technology research analyst, both at Merrill Lynch and Cowen & Co. She began her career at J.P. Morgan in a variety of roles, including healthcare investment banking, convertible sales/trading, and internal management consulting.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,135.72 +38.82 0.21%
S&P 500 2,101.04 +2.51 0.12%
NASDAQ 4,982.8090 +15.6680 0.32%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs